cyclobenzaprine · Tonmya

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Fibromyalgia

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also in development:Major Depressive Disorder · Phase 2

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (18)
Fibromyalgia
NCT05273749 · Tonix Pharmaceuticals, Inc.
2022-04-06 – 2023-11-14 · Fibromyalgia
What this study did
NCT02589275 · Tonix Pharmaceuticals, Inc.
2015-08-04 – 2016-09-28 · Primary Fibromyalgia
What this study did
NCT02829814 · Tonix Pharmaceuticals, Inc.
2016-07-22 – 2016-09-13 · Fibromyalgia, Myofascial Pain Syndromes, Muscular Diseases, Nervous System Diseases, Neuromuscular Diseases, Rheumatic Diseases, Musculoskeletal Diseases
What this study did
NCT02436096 · Tonix Pharmaceuticals, Inc.
2015-04 – 2016-09 · Fibromyalgia, Myofascial Pain Syndromes, Muscular Diseases, Musculoskeletal Diseases, Nervous System Diseases, Neuromuscular Diseases, Rheumatic Diseases
What this study did
NCT02015234 · Tonix Pharmaceuticals, Inc.
2013-12 – 2015-08 · Primary Fibromyalgia
What this study did
Other / comorbidity
NCT05683574 · Eurofarma Laboratorios S.A.
2026-05-30 – 2028-02-28 · Third Molar Extraction
What this study did
NCT03841773 · Tonix Pharmaceuticals, Inc.
2019-03-07 – 2020-04-24 · PTSD
What this study did
NCT03025113 · EMS
2018-03-08 – 2020-03-27 · Musculoskeletal Pain
What this study did
NCT02862977 · EMS
2017-11-10 – 2019-12-20 · Musculoskeletal Pain
What this study did
NCT02642861 · Tanta University
2018-10 – 2019-12 · Liver Cirrhosis
What this study did
NCT03508700 · Tonix Pharmaceuticals, Inc.
2018-04-19 – 2019-09-30 · PTSD
What this study did
NCT03062540 · Tonix Pharmaceuticals, Inc.
2017-03-27 – 2018-07-27 · PTSD
What this study did
NCT03110575 · Tonix Pharmaceuticals, Inc.
2017-06-20 – 2018-07-27 · PTSD
What this study did
NCT02814565 · Takeda
2016-10-12 – 2017-03-14 · Neck Pain, Back Pain, Spasm
What this study did
NCT01587508 · Eurofarma Laboratorios S.A.
2013-05 – 2013-05 · Acute Lumbago
What this study did
NCT01421433 · Farmoquimica S.A.
2012-05 – 2013-01 · Low Back Pain
What this study did
Phase 2/3 (1)
Fibromyalgia
NCT01903265 · Tonix Pharmaceuticals, Inc.
2013-09 – 2014-09 · Primary Fibromyalgia
What this study did
Phase 2 (7)
Major Depressive Disorder
Other / comorbidity
NCT06636786 · University of North Carolina, Chapel Hill
2025-03-25 – 2026-11 · Acute Stress Reaction, Acute Stress Disorder, Neurocognitive Function, Post-traumatic Stress
What this study did
NCT05472090 · Tonix Pharmaceuticals, Inc.
2022-08-18 – 2023-07-27 · Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection, COVID-19, Long COVID, Long Haul COVID
What this study did
NCT05372887 · Tonix Pharmaceuticals, Inc.
2022-10-14 – 2022-11-08 · PTSD
What this study did
NCT02421679 · Tonix Pharmaceuticals, Inc.
2015-04-14 – 2016-05-26 · PTSD
What this study did
NCT02277704 · Tonix Pharmaceuticals, Inc.
2014-10 – 2016-05 · PTSD
What this study did
NCT01921296 · Lynn Henry
2013-08 – 2015-04 · Sleep Initiation and Maintenance Disorders, Pain
What this study did
Phase 1 (8)
Other / comorbidity
NCT07413367 · Tonix Pharmaceuticals, Inc.
2025-12-09 – 2026-02-10 · Pharmakokinetic, Open Label, Phase 1
What this study did
NCT04164719 · Tonix Pharmaceuticals, Inc.
2019-10-14 – 2019-12-24 · Healthy Subjects
What this study did
NCT03443960 · Tonix Pharmaceuticals, Inc.
2018-01-29 – 2018-04-09 · Healthy Subjects
What this study did
NCT03353922 · Neurana Pharmaceuticals, Inc.
2017-07-31 – 2018-01-30 · Driving Impaired
What this study did
NCT03168022 · Tonix Pharmaceuticals, Inc.
2015-12-16 – 2016-01-26 · Healthy Adults
What this study did
NCT01889173 · Tonix Pharmaceuticals, Inc.
2013-06 – 2014-03 · Healthy Adults
What this study did
NCT01490788 · Tonix Pharmaceuticals, Inc.
2011-11-18 – 2011-12-30 · Healthy
What this study did
Phase 4 (4)
Fibromyalgia
NCT01041495 · State University of New York - Upstate Medical University
2009-06 – 2013-03 · Fibromyalgia, Pain, Sleep, Fatigue
What this study did
Other / comorbidity
NCT07664956 · Christiana Care Health Services
2026-07-01 – 2026-12-01 · Minimally Invasive Surgical Procedures, Abnormal Uterine Bleeding, Unspecified, Adenomyosis of Uterus, Fibroid Uterus, Chronic Pelvic Pain, Endometriosis, Menorrhagia, Endometritis, Adnexal Diseases
What this study did
NCT01587274 · Montefiore Medical Center
2012-04 – 2014-12 · Acute Low Back Pain
What this study did
NCT00246389 · McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
est. completion 2004-07 · Pain, Spasm
What this study did
Early phase / not applicable (4)
Other / comorbidity
NCT02974166 · Instituto Brasileiro de Osteopatia
2012-03 – 2016-08 · Temporomandibular Disorder
What this study did
NCT01081990 · Endeavor Health
2010-04 – 2014-08-01 · Postoperative Pain
What this study did
NCT01028014 · University of Alabama at Birmingham
2010-04 – 2011-04 · Urethral Sphincter Activity
What this study did
NCT00635037 · Federal University of São Paulo
2004-06 – 2006-11 · Myofascial Pain Syndromes
What this study did
Used as active comparator (5)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (1)
Phase 2 (1)
Other / comorbidity
NCT00790270 · Stony Brook University
2003-01 – 2004-01 · Cervical Strain
What this study did
Phase 1 (3)
Other / comorbidity
NCT04407377 · Neurana Pharmaceuticals, Inc.
2020-06-20 – 2021-03-31 · Healthy
What this study did
NCT01689259 · Tonix Pharmaceuticals, Inc.
2012-09 – 2014-03 · Healthy Adults
What this study did
NCT01634412 · Tonix Pharmaceuticals, Inc.
2012-06 – 2014-01 · Healthy Adults
What this study did
Appears in other studies (4)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 2/3 (1)
Other / comorbidity
NCT07404397 · University of Michigan
2026-02-18 – 2026-12 · High Tone Pelvic Floor Dysfunction
What this study did
Phase 1 (1)
Other / comorbidity
NCT00913419 · Sandoz
1988-11 – 1988-12 · Depression
What this study did
Phase 4 (1)
Other / comorbidity
NCT07840183 · Northwestern University
2026-09-25 – 2027-11 · Ventral Hernia, Ventral Hernia Repair, Postoperative Pain
What this study did
Early phase / not applicable (1)
Other / comorbidity
NCT00778037 · Ranbaxy Laboratories Limited
2006-09 – 2006-11 · Healthy
What this study did

Competitive landscape

This drug's own stage for Fibromyalgia: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Cyclobenzaprine (Tonmya): this drugApprovedSmall molecule5-HT2A, α1-adrenergic, H1-histaminergic, and M1-muscarinic acetylcholine receptors (functional antagonism)Partial signal
NCT04172831: Change in weekly average daily pain (NRS) from baseline to week 14: TNX-102 SL 5.6 mg -1.9 vs placebo -1.5; LS mean difference -0.4 (95% CI -0.7 to -0.1), p=0.010 (n=248 and 255) (CT.gov posted results).
NCT04508621: Change From Baseline to Week 14 in the Numerical Rating Scale (NRS) Weekly Average of Daily Self-reported Average Pain Severity Scores. (14 weeks): TNX-102 SL Tablet, 5.6 mg -1.6 score on a scale (95% CI -1.8 to -1.3) | Placebo SL Tablet -1.3 score on a scale (95% CI -1.5 to -1.1) missed
Duloxetine (Cymbalta)ApprovedSmall moleculeSerotonin/norepinephrine transporter, Serotonin and norepinephrine transporters (SERT/NET)not yet gradedNo reviewed efficacy summary in this indication
PregabalinApprovedSmall moleculeα2δ subunit of voltage-gated calcium channelsnot yet gradedNo reviewed efficacy summary in this indication
EsreboxetinePhase 3Small moleculenorepinephrine transporternot yet gradedNo reviewed efficacy summary in this indication
ONO-1110Phase 2Small moleculeEndocannabinoid synthesisnot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Tonmya (cyclobenzaprine) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
November 2026 (1)
Phase 2Acute Stress Reaction, Acute Stress Disorder, Neurocognitive Function, Post-traumatic StressRecruiting
Est. primary completion 2026-11 · NCT06636786 · CT.gov ↗
What to watch
2028 (1)
February 2028 (1)
Phase 2Major Depressive DisorderRecruiting
Est. primary completion 2028-02 · NCT07621237 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(3)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

15 August 2025ApprovalFDA approves Tonmya for fibromyalgia
US, FDA · Source ↗
15 August 2025FDA action datePDUFA goal date set for TNX-102 SL in fibromyalgia
US, FDA · Source ↗
17 December 2024Filing acceptedFDA accepts NDA for TNX-102 SL for fibromyalgia
US, FDA · Source ↗